What is Mogrify?
Mogrify is a biopharmaceutical entity dedicated to transforming the landscape of cell therapy development. The company's core focus lies in two key areas: enhancing the development of ex vivo cell therapies and pioneering novel in vivo reprogramming therapies. By leveraging cutting-edge scientific approaches, Mogrify seeks to address unmet medical needs and create new therapeutic paradigms. Its strategic positioning within the biopharmaceutical sector highlights a commitment to innovation and scientific rigor, aiming to translate complex biological research into tangible clinical solutions.
How much funding has Mogrify raised?
Mogrify has raised a total of $47.8M across 4 funding rounds:
Angel/Seed
$3.7M
Private Equity
$1.1M
Series A
$33M
Series A
$10M
Angel/Seed (2019): $3.7M with participation from 24Haymarket, Dr Disley, and Ahren
Private Equity (2020): $1.1M led by SBRI Healthcare
Series A (2021): $33M supported by University of Bristol Enterprise Fund III, Dr. Darrin Disley, Parkwalk Advisors, Dr. Jonathan Milner, Ahren Innovation Capital, Astellas Venture Management, and 24Haymarket
Series A (2023): $10M featuring Ahren Innovation Capital, Parkwalk Advisors, and Astellas Venture Management
Key Investors in Mogrify
24Haymarket
24Haymarket Limited is a private network of experienced investors and operators focused on capital investment. The company partners with exceptional entrepreneurs to provide funding and support for their ventures.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. With over 15 years of experience, they bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science. With over $400 million in available capital, they partner with exceptional founders and teams at all stages, from pre-seed to pre-IPO, to create and grow innovative businesses.
What's next for Mogrify?
With the recent infusion of capital, Mogrify is poised for accelerated growth and the expansion of its research and development initiatives. The company's strategic focus on both ex vivo and in vivo therapeutic modalities suggests a comprehensive approach to tackling complex diseases. Future endeavors will likely involve advancing its pipeline candidates through clinical trials, forging strategic partnerships, and further solidifying its technological infrastructure. The substantial backing indicates strong investor confidence in Mogrify's long-term vision and its potential to disrupt the biopharmaceutical market with its pioneering cell therapy solutions.
See full Mogrify company page
